Mistletoe in Cancer Cell Biology: Recent Advances
Current Issues in Molecular Biology · 20.08.2025 · 47 (8) · 672
DOI: 10.3390/cimb47080672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 20.08.2025. Verfasst von Chang-Eui Hong und 1 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Sunchon National University, Suncheon 57922, Republic of Korea. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mistletoe (Viscum album L.) has been used in complementary cancer therapy for decades, but its mechanisms remained poorly understood until recently. This review synthesizes transformative advances in mistletoe cancer research from 2020 to 2025, focusing on newly discovered molecular mechanisms, immunomodulatory properties, and clinical applications. We conducted a comprehensive analysis of controlled studies, mechanistic investigations, and real-world evidence published between 2020 and 2025. The discovery of mistletoe-induced immunogenic cell death (ICD) represents a paradigm shift in understanding its anticancer effects. Mistletoe extracts trigger endoplasmic reticulum stress, leading to calreticulin exposure in 18–51% of cancer cells and a 7-fold increase in adenosine triphosphate (ATP) release. Three-dimensional culture models revealed enhanced macrophage reprogramming effects, with a 15.8% increase in pro-inflammatory interleukin (IL)-6 and a 26.4% reduction in immunosuppressive IL-10. Real-world evidence from over 400 non-small-cell lung cancer patients shows that combining mistletoe with programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors doubles median overall survival (6.8 to 13.8 months), with biomarker-selected populations experiencing up to a 91.2% reduction in death risk. The Johns Hopkins Phase I trial established intravenous administration safety at 600 mg three times weekly. Advanced analytical approaches including metabolomics, chronobiology, and machine learning are enabling precision medicine applications. These findings position mistletoe as a scientifically validated component of integrative oncology, bridging traditional medicine with evidence-based cancer care. Future research should focus on ferroptosis mechanisms, single-cell immune profiling, and standardized clinical protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Pharmacy, Sunchon National University, Suncheon 57922, Republic of Korea.
- Smart Beautytech Research Institute, Sunchon National University, Suncheon 57922, Republic of Korea.
- Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea.
ORCID-Profile: Su-Yun Lyu
Zitieren
APA
Hong, C. E., & Lyu, S. Y. (2025). Mistletoe in Cancer Cell Biology: Recent Advances. Current Issues in Molecular Biology, 47(8), 672. https://doi.org/10.3390/cimb47080672
Vancouver
Hong CE, Lyu SY. Mistletoe in Cancer Cell Biology: Recent Advances. Current Issues in Molecular Biology. 2025;47(8):672. doi:10.3390/cimb47080672
BibTeX
@article{Hong2025,
author = {Hong, Chang-Eui and Lyu, Su-Yun},
title = {Mistletoe in Cancer Cell Biology: Recent Advances},
journal = {Current Issues in Molecular Biology},
year = {2025},
volume = {47},
number = {8},
pages = {672},
doi = {10.3390/cimb47080672}
}
EUVIMED